The ARF tumour suppressor protein (p14 ARF in human and p19 ARF in mouse) is a major mediator of the activation of p53 in response to oncogenic stress. Little is known about the signalling pathways connecting oncogenic stimuli to the activation of ARF. Regulation of ARF occurs primarily at the transcriptional level and several modulators of ARF transcription have been identi®ed. Notably, ectopic expression of E2F1 upregulates ARF transcriptionally, and both E2F1 and ARF have been implicated in apoptosis and cell-cycle arrest. We have used primary mouse ®broblasts de®cient for E2F1, E2F2, or both to determine the possible role of these E2F proteins as upstream regulators of ARF in response to oncogenic stimuli and other stresses. In particular, we have studied the eects of oncogenic Ras and the viral oncoprotein E1A on ARF levels, neoplastic transformation, and sensitization to apoptosis. We have also examined the behaviour of the E2F-de®cient MEFs with respect to immortalization and sensitivity to DNA damage. None of the ARFmediated responses that we have analysed is signi®cantly aected in E2F1 7/7 , E2F2 7/7 or E2F1/2 7/7 MEFs, and ARF is upregulated normally in all cases. Taken together, our results indicate that the activation of ARF in response to oncogenic stress can occur by E2F1-and E2F2-independent mechanisms. This challenges previous suggestions implicating E2F factors as key mediators in the activation of ARF by oncogenic stress.
Introduction
Normal mammalian cells possess safeguard mechanisms against tumorigenic stimuli (Weinberg, 1997) . These are designed to protect normal cells from aberrant mitogenic signals, DNA-damaging agents, or other stress signals, which have the potential to result in cellular transformation and eventually lead to tumour formation. The products of the INK4a/ARF locus play a pivotal role as sensors of oncogenic stress (reviewed in Sharpless and DePinho, 1999; Serrano, 2000; Sherr and DePinho, 2000; Sherr and Weber, 2000; Sherr, 2001a, b) . This locus encodes two structurally unrelated proteins (p16 INK4a and ARF) that act as tumour suppressors through independent pathways. The p16
INK4a protein is an inhibitor of cyclin dependent kinases (CDKs) , that negatively controls cell cycle progression at G1 by blocking phosphorylation of the retinoblastoma susceptibility protein (Serrano et al., 1993 Serrano, 1997) . Consistent with its role as a tumour suppressor, p16
INK4a function is lost in a large number of human tumours (Ruas and Peters, 1998) .
The ARF protein (p14 ARF in humans and p19 ARF in the mouse) exerts its tumour suppressor action by activating the p53 pathway (reviewed in Prives, 1998; Sherr, 1998 Sherr, , 2001a . ARF controls the levels of the p53 protein thanks to its interaction with Mdm2 which interferes with Mdm2-mediated degradation of the p53 protein by the proteasome (Ashcroft and Woods and Vousden, 2001) . Among the dierent types of stimuli that trigger p53 activation (Vogelstein et al., 2000) , ARF mediates p53 activation by inappropriate growth signals, such as expression of cellular or viral oncogenes (de Stanchina et al., 1998; Palmero et al., 1998; Radfar et al., 1998; Zindy et al., 1998) . On the other hand, ARF is dispensable for short-term activation of p53 by DNA damage (Kamijo et al., 1997; Khan et al., 2000; revised in Prives, 1998; Sherr, 1998; Sherr and Weber, 2000) . Consistent with the role of ARF as a tumour suppressor, mice genetically de®cient for p19 ARF (but retaining full p16
INK4a function) are highly tumourprone (Kamijo et al., 1997 (Kamijo et al., , 1999 .
Overexpression of the transcription factor E2F1 is one of the promitogenic stimuli known to induce ARF expression (DeGregori et al., 1997; Zindy et al., 1998; Llanos et al., 2001) , and this is a result of direct transcriptional activation of the ARF promoter by E2F1 Robertson and Jones, 1998; Inoue et al., 1999; Moroni et al., 2001) . The E2F family of transcription factors plays an important role in the control of cell cycle progression in connection with the family of`pocket proteins' (Rb, p107 and p130) (Dyson, 1998; Trimarchi and Lees, 2002) . Phosphorylation of pocket proteins by CDKs, at G1, results in the release of active E2F factors which, in this manner, activate a number of target genes required for cell-cycle progression (Sherr, 1996; Harbour and Dean, 2000; Ishida et al., 2001; Muller et al., 2001) . In mammalian cells, there are six E2F members, which form heterodimers with members of the DP family. In addition to the wellestablished role of E2F activity in the control of cell-cycle progression, a role in apoptosis has also been reported. This property has been ascribed primarily to E2F1 and, to a lesser extent, to E2F2 and E2F3 (Kowalik et al., 1995 (Kowalik et al., , 1998 DeGregori et al., 1997; Wu and Levine, 1997; Vigo et al., 1999; Humbert et al., 2000; Leone et al., 2001; Ziebold et al., 2001) . The proapoptotic role of E2F1 is supported by the defects in apoptosis observed in E2F1 knock-out mice (Field et al., 1996; Yamasaki et al., 1996; Zhu et al., 1999; Garcia et al., 2000) . The analysis of animals individually de®cient for E2F1 or E2F2 has revealed that these proteins play non-redundant functions in the immune system. In particular, E2F1 functions as a promoter of apoptosis and proliferation in T-cells, while E2F2 is a negative regulator of T-cell proliferation (Field et al., 1996; Yamasaki et al., 1996; Garcia et al., 2000; Murga et al., 2001) . Apoptosis induced by E2F1 seems to involve several dierent pathways such as activation of p53 (Phillips et al., 1997; Kowalik et al., 1998; Pan et al., 1998) , activation of the p53-related protein p73 Lissy et al., 2000) , downregulation of the survival factor TRAF2 , and induction of the proapoptotic factor Apaf-1 .
The connection of E2F1 with p53 accumulation and apoptosis, together with the existing evidence linking E2F1 to the ARF tumour suppressor, prompted us to explore the role of E2F1 (and its relative E2F2) in the activation of p19 ARF . For this, we have used primary mouse embryonic ®broblasts from animals genetically de®cient for E2F1, E2F2, or both, and have analysed their response to oncogenic Ras, the viral oncoprotein E1A, replicative senescence, and DNA damage. The choice of ®broblasts to study these responses in relation to ARF is based on a number of reasons. First, upregulation of ARF in response to a variety of stresses has been best characterized in primary ®broblasts (de Stanchina et al., 1998; Palmero et al., 1998; Radfar et al., 1998; Zindy et al., 1998; Khan et al., 2000) . Also, overexpression of E2F1 in ®broblasts can induce both senescence and apoptosis (DeGregori et al., 1997; Zindy et al., 1998; Dimri et al., 2000) , two responses which could be mediated by ARF. Finally, rodent ®broblasts detectably express both E2F1 and E2F2 (Rempel et al., 2000; Leone et al., 2001) .
Results

Effect of oncogenic Ras in MEFs deficient for E2F1 and E2F2
Primary cells respond to the sustained expression of oncogenic Ras by activating a permanent cell-cycle arrest reminiscent of cellular senescence . This is accompanied by the induction of several negative cell-cycle regulators including p53 and both products of the INK4a/ARF locus, p16
INK4a and p19 ARF Palmero et al., 1998) . In MEFs, the existence of a functional ARF/p53 pathway is required for this response. MEFs which are p19 ARFor p53-null do not show Ras-induced arrest and rather become transformed (Kamijo et al., 1997; Serrano et al., 1997; Palmero et al., 1998) . To examine the role of E2F factors in the induction of p19 ARF and cell-cycle arrest by oncogenic Ras, we analysed the eect of the activated form of the human Harvey Ras protein (HaRas G12V, hereafter designated as RasV12) in MEFs of dierent genotypes, using retroviral transduction ( Figure 1 ). As described previously Palmero et al., 1998) , wild-type MEFs displayed a signi®cant reduction in their proliferation rate (Figure 1a) , together with increased levels of p19 ARF and p53 (Figure 1b) . In contrast, p53 7/7 cells proliferated at higher rates in the presence of RasV12. Importantly, MEFs de®cient for E2F1, E2F2, or both, showed reduced proliferation in the presence of RasV12, a behaviour comparable to that observed in . Consistent with this, p19 ARF levels were increased in RasV12-expressing MEFs and this resulted in normal accumulation of p53 ( Figure 1b ). As previously described by others , we observed higher basal levels of p19 ARF in p53-null MEFs, presumably as a result of the negative feed-back loop existing between p53 and ARF (Robertson and Jones, 1998; Stott et al., 1998) . These results suggest that E2F1 and E2F2 do not play a critical role in the activation of p19 ARF by oncogenic Ras in primary MEFs.
Oncogenic Ras eciently causes neoplastic transformation in primary MEFs lacking proteins essential for Ras-induced cell-cycle arrest, such as p53 7/7 , INK4a/ ARF 7/7 or ARF 7/7 (Harvey et al., 1993; Jones et al., 1996; Serrano et al., 1996; Kamijo et al., 1997) . To study the susceptibility of E2F1 7/7 , E2F2 7/7 , or E2F1/2 7/7 MEFs to neoplastic transformation, we measured their ability to form foci following standard transfection with RasV12 (Table 1) . Consistent with the results described in Figure 1 , we could not detect any foci with E2F-null MEFs transfected with RasV12. Taken together, these results indicate that MEFs de®cient for E2F1, E2F2, or both, are not permissive to neoplastic transformation by oncogenic Ras.
Senescence and immortalisation in MEFs deficient for E2F1 and E2F2
Accumulation of population doublings in MEFs causes a dramatic increase in p16
INK4a and p19 ARF protein levels (Palmero et al., 1997; Zindy et al., 1997 Zindy et al., , 1998 Pantoja and Serrano, 1999) . Also, overexpression of E2F1 has been reported to induce a senescent phenotype in human primary ®broblasts, associated to p14 ARF upregulation (Dimri et al., 2000) . These observations led us to analyse the eects of the absence of E2F1 and E2F2 on senescence and immortalization. We cultivated primary MEFs of dierent genotypes following a 3T3 serial passage protocol (Todaro and Green, 1963) . After a period of active growth (approximately 10 ± 12 PDL), wild-type and E2F-null MEFs reduced their growth and entered senescence with similar kinetics (data not shown). We then compared levels of p19 ARF , p16 INK4a , and p53 proteins in early-and late-passage MEFs. As expected, all three proteins showed marked increases in late-versus earlypassage wild-type cells and, more importantly, similar results were obtained for E2F1 7/7 , E2F2 7/7 or double null E2F1/2 7/7 MEFs ( Figure 2 ). The ability of primary MEFs to form visible colonies when seeded at low density is a practical and quantitative way to measure the proliferative potential of these cells. Under the appropriate conditions, only cells which are able to escape senescence divide enough times to form visible colonies (see for example Harvey et al., 1993; Serrano et al., 1996; Kamijo et al., 1997) . We carried out three independent colony formation assays, using MEFs from dierent embryos in each case. As expected (Harvey et al., 1993; Jones et al., 1996; Serrano et al., 1997; Pantoja and Serrano, 1999) , p53 7/7 cells were able to form colonies with high eciency whereas wild-type MEFs did not form any colonies (Table 2 ). In contrast to p53 7/7 cells, E2F-null MEFs consistently formed a low number of colonies (Table 2 ). This indicates that the absence of E2F1 and/or E2F2 does not represent a signi®cant proliferative advantage to MEFs and, therefore, does not mimic the absence of p19 ARF or p53 (Harvey et al., 1993; Jones et al., 1996; Kamijo et al., 1997) .
Proapoptotic response to E1A in MEFs deficient for E2F1 and E2F2
The adenoviral oncoprotein E1A sensitizes primary cells to mild apoptotic stimuli through the accumulation of p53, in a process mediated by p19 ARF (Lowe and Ruley, 1993; de Stanchina et al., 1998) . Also, as mentioned, E2F1 and, to a lesser extent, E2F2 and E2F3, have been implicated in induction of apoptosis (Kowalik et al., 1995 (Kowalik et al., , 1998 Field et al., 1996; Yamasaki et al., 1996; DeGregori et al., 1997; Wu and Levine, 1997; Vigo et al., 1999; Zhu et al., 1999; Garcia et al., 2000; Leone et al., 2001) . In an eort to determine whether E2F1 or E2F2 could be involved in the activation of p19 ARF by E1A, we retrovirally infected primary MEFs with a vector expressing E1A. After selection of infected cells, we considered the MEFs (Figure 3a) , or ARF 7/7 MEFs (data not shown; see also Lowe and Ruley, 1993; de Stanchina et al., 1998) . MEFs of E2F1 7/7 , E2F2 7/7 , or E2F1/ 2 7/7 genotype showed a slight reduction of apoptosis which was more obvious for E2F2 7/7 or E2F1/2 7/7
MEFs, both in the presence or absence of adriamycin. This eect was nevertheless not comparable to the almost complete protection observed in p53 7/7 or ARF 7/7 MEFs (Figure 3a ; see also de Stanchina et al., 1998) . Similar results were obtained using low-serum conditions (0.5%) as a proapoptotic stimulus (data not shown; see also Lowe and Ruley, 1993) . We then looked at the eect of E1A on p19 ARF and p53 protein levels by Western blot (Figure 3b ). MEFs de®cient for E2F1, E2F2, or both, showed an induction of p19 ARF comparable to that observed in wild-type cells and this was re¯ected in normal accumulation of p53, consistent with the described requirement of p19 ARF for p53 induction in this setting (de Stanchina et al., 1998) . From these experiments we can conclude that E2F1 and E2F2 do not play a signi®cant role in the induction of p19 ARF , the accumulation of p53, and the proapoptotic state induced by the viral oncoprotein E1A.
Growth properties of MEFs expressing E1A and RasV12
To gain insights into the role of E2F1 and E2F2 in neoplastic transformation, we have analysed the combined eects of RasV12 and E1A. Expression of E1A renders primary normal cells susceptible to transformation by RasV12, presumably due to inactivation of Rb and the related proteins p107 and p130 Sage et al., 2000) . To evaluate neoplastic transformation, we performed retroviral infections with a vector co-expressing RasV12 and E1A linked by an IRES element and measured the ability of MEFs of dierent genotypes to form colonies in soft agar (Figure 4a ). MEFs of wild-type genotype were able to form a signi®cant number of colonies when expressing E1A and RasV12. Absence of p53 resulted in a high eciency in colony formation, presumably due to protection against E1A-induced apoptosis (Figure 4a ; see also Lowe and Ruley, 1993) . In contrast to p53 de®ciency, absence of E2F1 or E2F2 did not have a dramatic impact in the transformation of primary mouse ®broblasts by E1A and RasV12. A similar number of colonies was observed for wild-type, E2F2 and E2F1/2-null MEFs expressing E1A-RasV12 ( Figure  4a ). E2F1 7/7 MEFs formed more colonies in this assay (approximately threefold), probably re¯ecting some degree of protection against E1A-induced apoptosis.
Previous reports have suggested that de®ciency in another member of the E2F family, E2F3, results in a reduced proliferative rate of E1A-RasV12 transformed MEFs (Humbert et al., 2000) . To assess if this was the case for E2F1 and E2F2, we measured the proliferation rate of MEFs retrovirally infected with E1A-RasV12 (Figure 4b ). Wild-type transformed cells showed a vigorous proliferative rate, as expected. Cells of all three E2F-de®cient genotypes proliferated at levels similar to wild-type, suggesting that, unlike E2F3, E2F1 and E2F2 are not required either for ecient transformation or for the subsequent proliferation of transformed mouse ®broblasts. 
Long-term response to DNA damage in MEFs deficient for E2F1 and E2F2
Another setting where E2F factors could be linked to ARF and p53 activation is in the response to DNA damage. There is substantial evidence indicating that E2F1 (but not other E2Fs) accumulates in cells exposed to a variety of genotoxic agents (Huang et al., 1997; Blattner et al., 1999; Hoerer et al., 1999; Meng et al., 1999; Lin et al., 2001) . This increase in E2F1 protein is due to protein stabilization mediated by direct phosphorylation of E2F1 by the ATM kinase (Lin et al., 2001) . Also, thymocytes from E2F1 7/7 mice show an attenuated apoptotic response to DNA damage (Lin et al., 2001) . Additionally, previous work has shown that p19 ARF de®ciency partially impairs long term cell-cycle arrest induced by g-radiation (24 h after treatment, Khan et al., 2000) . In order to analyse the contribution of E2F1 to the DNA damage response in ®broblasts, MEFs of E2F1 7/7 , ARF 7/7 and p53 7/7 genotypes were exposed to sublethal doses of radiation (6 Gy) and 24 h later we evaluated their biological response ( Figure 5 ). The cell-cycle arrest induced by gradiation is fully dependent on p53 (Di Leonardo et al., 1994; Khan et al., 2000) and, accordingly, p53
MEFs did not show any reduction in their proliferative rate ( Figure 5 ). In keeping with recent work (Khan et al., 2000) , disruption of p19 ARF partially eliminated this arrest. However, the absence of E2F1 had a minor eect on the ability of mouse ®broblasts to arrest in response to g-radiation (53% reduction in S phase in E2F1 7/7 versus 61% in wild-type cells). A similar lack of eect was observed with E2F2
7/7 cells (data not shown). We conclude that absence of E2F1 or E2F2 does not impair the cell-cycle arrest triggered by gradiation in mouse ®broblasts.
Discussion
In this study we have used a genetic approach to investigate the involvement of E2F1 and E2F2 in the activation of p19 ARF by several oncogenic stresses and their participation in biological responses mediated by ARF. The rationale for these studies is based on a variety of evidences that link overexpression of E2F1 to induction of ARF through direct transcriptional activation Robertson and Jones, 1998; Inoue et al., 1999; Moroni et al., 2001) . E2F1 is able to induce apoptosis, in part through a p53-dependent mechanism (Kowalik et al., 1995 (Kowalik et al., , 1998 ; DeGregori et al., 1997; Wu and Levine, 1997) , and is also able to induce senescence (Dimri et al., 2000) . These observations have led to a model where E2F1 is functionally connected to p53 via its activation of ARF. Challenging this model, we have found that primary mouse ®broblasts individually de®cient for E2F1 or E2F2, or double mutants de®cient for both, display a normal behaviour in a variety of settings where ARF plays an important biological role. Unlike ARF 7/7 MEFs, MEFs de®cient for E2F1, E2F2, or both, are not immortal, rather enter senescence normally and are not permissive to direct transformation by oncogenic Ras. Likewise, they are sensitive to Ras-induced cell-cycle arrest and E1A-induced apoptosis, also the induction of ARF that normally occurs in the above-mentioned situations is not impaired in the E2F-null cells that we have analysed. Similarly, we have not observed a marked de®ciency in the cell-cycle arrest elicited by g-radiation, a response where E2F1 and ARF have been previously implicated (Huang et al., 1997; Blattner et al., 1999; Hoerer et al., 1999; Meng et al., 1999; Khan et al., 2000; Lin et al., 2001) . From these studies, we have concluded that, in mouse ®broblasts, E2F1 and E2F2 do not play a critical role in the activation of ARF by oncogenic stress, senescence, or DNA damage.
A number of explanations can be put forward to explain the apparent con¯ict between our observations and previous reports linking E2F to ARF. Notably we have used primary mouse ®broblasts de®cient for E2F1 and/or E2F2 whereas all previous studies were based on overexpression experiments. (DeGregori et al., 1997; Bates et al., 1998; Zindy et al., 1998; Llanos et al., 2001) . Therefore, our results are expected to evaluate more faithfully the actual role of the endogenous proteins. Redundancy within the E2F family could also account for the observed lack of phenotype. So far, only E2F1 and E2F2 have been implicated in ARF activation (DeGregori et al., 1997; Bates et al., 1998) and, for this reason, we included in our study MEFs obtained from double E2F1/E2F2 knock-out animals. Nevertheless, we cannot formally rule out the existence of functional compensation by other E2Fs in the double null cells. In particular, E2F3 shares structural and functional features with E2F1 and E2F2 (Trimarchi and Lees, 2002) and, therefore, it is the best suited candidate for such a compensatory eect. However, we consider unlikely that E2F3 could compensate the absence of E2F1 and E2F2. On one hand, the ability of E2F3 to induce apoptosis has not been unambiguously established and there are con¯ict-ing reports in this respect (DeGregori et al., 1997; Vigo et al., 1999; Humbert et al., 2000; Leone et al., 2001; Ziebold et al., 2001) . On the other hand, it has been reported that overexpression of E2F3 does not result in ARF induction (DeGregori et al., 1997) . Finally, we have analysed E2F3 protein levels and have failed to detect overexpression of E2F3 in MEFs de®cient for E2F1, E2F2 or both (data not shown), indicating that there is no compensatory upregulation of E2F3. This is consistent with the published data on E2F3 levels in lymphocytes of E2F1/2 7/7 genotype (Zhu et al., 2001 ). In any case, ®nal proof of the possible involvement of E2F3 in ARF-mediated responses should await analysis of MEFs de®cient for E2F1, E2F2 and E2F3, although the reduced proliferative capacity of these cells makes these studies complicated . Finally, it is also conceivable that the eects of E2F1 and E2F2 are cell-type speci®c. In support to this, animals de®cient for E2F1 or E2F2 show evident alterations in proliferation and apoptosis in lymphoid organs, but very limited phenotypic defects in other organs (Field et al., 1996; Yamasaki et al., 1996; Garcia et al., 2000; Murga et al., 2001; Zhu et al., 2001) .
The transcriptional activity of the ARF promoter seems to be subjected to a rather complex regulation, probably requiring the combined action of several transcription factors. Apart from E2F1, a number of transcription factors have been identi®ed so far as playing a role in ARF regulation, either as positive or negative regulators. The positive regulators include Myc , and DMP1 (Inoue et al., 1999 (Inoue et al., , 2000 ; and the negative regulators include p53 Robertson and Jones, 1998) , Twist (Maestro et al., 1999) , Bmi-1 (Jacobs et al., 1999) , JunD (Weitzman et al., 2000) , TBX2 (Jacobs et al., 2000) and TBX3 (Brummelkamp et al., 2001) . There is evidence for direct transcriptional regulation of the ARF promoter in the cases of E2F1, DMP1, TBX2 and TBX3 Inoue et al., 1999; Jacobs et al., 2000; Brummelkamp et al., 2001 ). Inoue and coworkers have analysed the impact of the targeted disruption of the DMP1 gene in ARF regulation (Inoue et al., 2000) . The absence of DMP1 has a clear eect in facilitating immortalization and oncogenic transformation of MEFs, however, this occurs with only partial impairment of ARF regulation. Similarly, overexpression of the transcriptional repressors TBX2 or TBX3 in MEFs results in immortalization but, interestingly, not full transformation with oncogenic Ras (Jacobs et al., 2000; Brummelkamp et al., 2001) . These observations, together with the data presented here, suggest that factors other than the E2F family, such as the positive regulator DMP1, or the negative regulators TBX2 and TBX3 are the major mediators in the activation of ARF in response to oncogenic stress.
A further level of complexity arises from recent reports which described the existence of physical interaction between ARF and E2F proteins (Eymin et al., 2001; Martelli et al., 2001) . These authors concluded that the growth suppressor activity of ARF is not exclusively exerted through the stabilization of p53, but also through ARF-induced destabilization of E2F1 protein. Although we have not addressed this issue directly, a conclusion from our experiments is that, at least in murine ®broblasts, endogenous p19 ARF does not seem to require functional E2F1 or E2F2 to exert its biological activity.
E2Fs are downstream eectors of the retinoblastoma protein (Dyson, 1998; Harbour and Dean, 2000) . The results we present here are in agreement with the E2F-independent activation of ARF I Palmero et al concept that, compared to the ARF/p53 pathway, the pathway controlled by Rb plays a secondary role in senescence and sensitivity to oncogenic stress in mouse ®broblasts (Dannenberg et al., 2000; Sage et al., 2000; Krimpenfort et al., 2001; Peeper et al., 2001; Sharpless et al., 2001; Sherr, 2001a) . In summary, we have shown that mouse primary ®broblasts de®cient for E2F1 and E2F2 display a normal behaviour in several biological responses mediated by ARF, including replicative senescence, immortalization, DNA damage and sensitivity to the oncogenes Ras and E1A. Consistent with this, ARF induction in these settings is independent of E2F1 and E2F2. Very recently, two reports have demonstrated that E2F1 can trigger p53-dependent apoptosis independently of ARF (Hsieh et al., 2002; Tolbert et al., 2002) and this could be mediated by direct interaction between E2F proteins and p53 (Hsieh et al., 2002) . Taken together, these results and ours show that ARF and E2F can activate p53-mediated responses through independent mechanisms. This highlights the complexity of the transcriptional regulation network responsible for the control of ARF in response to oncogenic stimuli and other types of stress.
Materials and methods
Animal colonies
Colonies of wild-type, p53 7/7 (Jacks et al., 1994) and ARF 7/7 (Kamijo et al., 1997) mice were maintained at the CNB, Madrid, in a mixed genetic background C57Bl6 : 129Sv.
Colonies of E2F1
7/7 (Field et al., 1996) , E2F2 7/7 (Murga et al., 2001) , and double null E2F1/2 7/7 mice were maintained at the UPV, Bilbao, also in a C57Bl6 : 129Sv background.
Cell culture
Mouse embryonic ®broblasts (MEFs) were prepared from embryos of the dierent genotypes at day 13.5 of gestation as previously described (Pantoja and Serrano, 1999; Palmero and Serrano, 2001) . After disgregation of embryos and brief expansion, MEFs from individual embryos were stored in liquid nitrogen until use. Plating of MEFs after thawing was considered passage 1. Cells were maintained in DMEM medium containing 10% foetal bovine serum and a cocktail of antibiotics and antimycotic in a CO 2 incubator at 378C.
Retroviral infection of MEFs, thymidine incorporation assays, serial passage of MEFs, colony formation assays, growth in soft agar, and foci formation assays were carried out essentially as described Pantoja and Serrano, 1999; Palmero and Serrano, 2001 ). Brie¯y, 8610 5 early passage MEFs were used for retroviral transduction. After selection (generally 3 ± 4 days after infection), 2610 3 cells were plated per well, in triplicate, in a 96-well plate and thymidine incorporation was measured at the indicated times. Protein extracts were prepared at day 2 postselection (see below).
For serial passage, we seeded 1610 6 cells in a 100-mm dish and, 3 days later, cells were trypsinized, counted, an seeded at the same density. The process was repeated for, at least, 20 passages. For colony formation assays, early passage MEFs were plated at a density of 2610 3 cells per 100-mm dish, in triplicate and, 2 weeks later, the number of colonies larger than 1.5 mm in diameter was scored. In foci formation assays, 1610 6 MEFs were plated in a 100-mm dish and subject to calcium phosphate transfection using 10 mg of the indicated DNAs. Two weeks later, the number of morphologically transformed foci was counted. For soft agar growth, 3610 5 cells, previously transduced with the indicated retroviruses, were resuspended in normal medium containing 0.3% low melting agarose (LMP agarose, BioRad) and plated onto 60-mm dishes coated with a layer of 0.5% low melting agarose in complete medium. The plates were incubated for 2 weeks with regular replenishing of medium and the colonies were counted visually.
Drug sensitivity
To assay the proapoptotic eects of E1A, early passage MEFs were retrovirally transduced with a vector expressing E1A12S (pWZLHygro-E1A) or the corresponding empty vector. After selection, 1610 6 cells were plated per 100-mm dish, and adriamycin (Farmiblastina, Pharmacia-Upjohn) was added to the medium at a ®nal concentration of 0.2 mg/ml. Forty-eight hours later, attached and¯oating cells were harvested and processed for protein analysis, viability assays and¯ow cytometry analysis.
Gamma-irradiation
Exponentially growing cultures of MEFs were exposed to a single dose of 6 Gy, using a 137 Cs irradiator (MARK 1-30, Shepherd and Associates), at a rate of 4.1 Gy/min. Cells (both attached and¯oating) were processed at the indicated times for Western blot and¯ow cytometry.
Flow cytometry
Approximately 1610 5 cells were lysed and stained with propidium iodyde using the DNA-Prep reagents (Coulter Corporation). The samples were then analysed in an Epics XL cytometer (Coulter Corportion). Events with sub G0-G1 DNA contents were considered to correspond to apoptotic cells. In some cases, cell viability was also determined by trypan blue exclusion (Lowe and Ruley, 1993) .
Western blot analysis
Preparation of total cell extracts, electrophoresis in 12% acrylamide SDS gels, and Western blot analysis were carried out as previously described (Pantoja and Serrano, 1999) . The following primary antibodies were used: anti-p19 ARF (R562, AbCam, 1 : 200 dilution), anti-p16 (M-156, Santa Cruz, 1 : 200) and anti-p53 (CM-5, Novocastra, 1 : 200). To control for integrity of samples and equal loading, we used an anti-b actin antibody (AC-15, Sigma, 1 : 10 000). After incubation with horseradish peroxidase-coupled secondary antibodies (donkey anti-rabbit, Amersham, 1 : 1000, and goat antimouse, Dako, 1 : 1000), signals were detected by chemiluminescence using ECL (Amersham) following the manufacturers' instructions.
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